Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S038 - Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management

Sunday, February 18; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize the physical lesions that constitute hidradenitis suppurativa / acne inversa, their characteristic distribution, and their tendency to recur over time.
  • Select appropriate preventive, medical and surgical therapies for patients with hidradenitis suppurativa.

Description

This session will begin with a review of the epidemiology and comorbidities of HS, diagnosis of HS and phenotypes, and current concepts of HS pathogenesis. A general approach to medical treatment will be discussed, including topical, intralesional, and oral treatments, as well as biologics. Surgical procedures for HS will be presented by a dermatologic surgeon, as well as when to refer to a surgeon. The importance of a multi-specialty approach, lifestyle modifications, and support groups will be discussed. The development of the North American guidelines for treatment will also be presented. There will be a Q&A session with the faculty.

Disclosures

  • Alavi, Afsaneh, MD: AbbVie – A(H), I(Grants/Research Funding), Speaker/Faculty Education(Grants/Research Funding); Actelion – A(Fees); Asana Biosciences, LLC – I(Grants/Research Funding); Boehringer Ingelheim – I(Fees); Canadian Dermatology Association – B(NC); Celgene – SP(Fees); Dermavant Sciences – I(Fees); DS Biopharma – I(Fees); Eli Lilly and Company – I(Fees); Galderma Canada, Inc – A(H), I(Fees); Glenmark Generics Inc. – I(Fees); Incyte Corporation – I(Fees); InflaRx – I(Fees); Janssen Pharmaceuticals, Inc – A(H); LEO Laboratories Ltd (LEO Pharma) – SP(Fees); Leo Pharma Inc – I(Fees); Novartis – I(Fees); Regeneron – I(Grants/Research Funding); UCB – I(Fees); Valeant Pharmaceuticals North America LLC – A(H); XOMA (US) LLC – I(Grants/Research Funding);
  • Brassard, Alain, MD: AbbVie – A(H); Janssen-Ortho Inc. – A(H), SP(H);
  • Garg, Amit, MD: AbbVie – A(H), I(Grants/Research Funding); Asana Biosciences, LLC – A(H); National Psoriasis Foundation – I(Grants/Research Funding); Pfizer Inc. – A(H); UCB – C(H);
  • Jemec, Gregor B.E., MD: AbbVie – A(H), I(Grants/Research Funding); Astion Pharma – C(H); Desitin Arzneimittel GmbH – Speaker/Faculty Education(NC); InflaRx GmbH – A(H), C(H), I(Grants/Research Funding); Janssen-Ortho Inc. – I(Grants/Research Funding); LEO Pharma, US – I(Grants/Research Funding); Michelson Diagnostics Ltd. – I(NC); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); UCB – A(H);
  • Kimball, Alexandra Boer, MD, MPH: AbbVie – C(H), I(Grants/Research Funding); Dermira – C(H); Escalier Biosciences – A(H), A(OB); Janssen Biotech – C(H); Janssen Pharmaceuticals, Inc – I(Residency/Fellowship Program Funding); Lilly ICOS LLC – C(H); Merck & Co., Inc – C(H); New Enterprise Associates – C(H); Novartis – C(H); Procter & Gamble Company – C(H); Regeneron – C(H); Sanofi/Regeneron – C(H); UCB – C(H);
  • Lowes, Michelle Anne, MBBS, PhD: AbbVie – C(Fees); Incyte Corporation – C(Fees); XBiotech – C(Fees);
  • Parks Miller, Angela: AbbVie – A(H), C(Fees);
  • Resnik, Barry I., MD: no financial relationships exist with commercial interests.
  • Sayed, Christopher John, MD: AbbVie – A(Fees), I(Fees), SP(Fees); GlaxoSmithKline – I(Fees); InflaRx – I(Grants/Research Funding); Novartis – I(Fees), SP(NC); Tioga Pharmaceuticals, Inc. – I(Fees);
Schedule
Sunday, February 18
1:00 PM
Dr. Lowes / Introduction
1:05 PM
Dr. Garg / Epidemiology & comorbidities of hidradenitis suppurativa
1:25 PM
Dr. Brassard / Diagnosis of hidradenitis suppurativa & phenotypes
1:45 PM
Dr. Lowes / Pathogenesis of hidradenitis suppurativa
2:00 PM
Dr. Jemec / Microbiome in hidradenitis suppurativa
2:15 PM
Dr. Lowes, Dr. Garg, Dr. Brassard, and Dr. Jemec / Q&A session
2:25 PM
/ Break
2:30 PM
Parks-Miller / Lifestyle modifications & support groups for hidradenitis suppurativa
2:45 PM
Dr. Kimball / Medical treatment of hidradenitis suppurativa
3:05 PM
Dr. Resnik / Surgical treatment of hidradenitis suppurativa
3:25 PM
Dr. Alavi / Wound healing in hidradenitis suppurativa
3:40 PM
Dr. Sayed / Development of North American hidradenitis suppurativa treatment guidelines
3:50 PM
Dr. Kimball, Dr. Resnik, Dr. Alavi, and Dr. Sayed / Q&A session
Event Details
  • Date
    Sunday, February 18
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 9
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Michelle Anne Lowes, MBBS, PhD
Speakers
  • Afsaneh Alavi, MD, FAAD
  • Alain Brassard, MD, FAAD
  • Alexandra Boer Kimball, MD, MPH, FAAD
  • Amit Garg, MD, FAAD
  • Angela Parks Miller
  • Barry I. Resnik, MD, FAAD - Handout
  • Christopher John Sayed, MD, FAAD
  • Gregor B.E. Jemec, MD